Cambodia vs Zimbabwe: Average cost of multi drug-resistant tuberculosis treatment
Cambodia
850 constant 2022 US$
in 2024
Zimbabwe
851 constant 2022 US$
in 2023
Cambodia rank
58th
Zimbabwe rank
57th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cambodia
- Zimbabwe
How they compare
Zimbabwe currently reports 851 constant 2022 US$ against 850 constant 2022 US$ in Cambodia, a difference of 1 constant 2022 US$.
Across all 6 years both countries report, Cambodia has been ahead every year.
Cambodia ranks 58th and Zimbabwe ranks 57th of 92 countries.
Cambodia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cambodia | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,247 constant 2022 US$ | 1,672 constant 2022 US$ | 575 constant 2022 US$ | Cambodia |
| 2020s | 1,967 constant 2022 US$ | 617.33 constant 2022 US$ | 1,349 constant 2022 US$ | Cambodia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cambodia or Zimbabwe?
- Zimbabwe, at 851 constant 2022 US$ against 850 constant 2022 US$ in Cambodia as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cambodia and Zimbabwe?
- 1 constant 2022 US$, with Zimbabwe ahead.
- How many years of comparable data are there for Cambodia and Zimbabwe?
- 6 years are reported by both, from 2017 to 2023.
- How do Cambodia and Zimbabwe rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cambodia ranks 58th and Zimbabwe ranks 57th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.